logo
  

M.D.C. Holdings Q2 Profit Plunges, Yet Beats View - Quick Facts

M.D.C. Holdings, Inc. (MDC), a homebuilding and financial services company, reported Tuesday that its second-quarter net income was $21.54 million or $0.44 per share, compared to $224.91 million or $4.55 per share last year.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.40 per share for the quarter. Analysts' estimates typically exclude special items.

The prior year results included a $187.6 million benefit from the reversal of deferred tax asset valuation allowance, while the firm had no such benefit for the 2014 second quarter.

Pretax income was $34.0 million, compared to $38.0 million for the same period in the prior year.

Total home and land sale revenues increased to $431.26 million from $402.13 million last year. Analysts expected revenues of $411.38 million.

Home sale revenues increased 8 percent to $430.7 million, primarily from a 10 percent increase in average selling price to $372,000.

Net new orders went up 5 percent to 1,419 homes, and dollar value of net new orders of $544.8 million went up 12 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast. AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT